Temasek Leads Series B Round in Hangzhou Just Biotherapeutics

Institutional investors are taking a deeper look into China’s healthcare sector, especially in the area of biotherapeutics. Singapore’s Temasek Holdings led a Series B round in Hangzhou Just Biotherapeutics, Ltd. (Just China), a company focused on developing global antibody and recombinant protein bio-therapeutics. [ Content protected for Sovereign Wealth Fund Institute Standard subscribers only. Please subscribe to view content. ]

Contact the writer or creator of this article or page.
Questions or comments: support(at)swfinstitute(dot)org
Follow on Twitter at @swfinstitute and @sovereignfunds
Learn, Attend and Network: Institutional Investor Events and Summits
Go Back: HOME: Sovereign Wealth Fund Institute

institutional investor investment mandates